Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

114 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
MITO39: Efficacy and Tolerability of Pegylated Liposomal Doxorubicin (PLD)-Trabectedin in the Treatment of Relapsed Ovarian Cancer after Maintenance Therapy with PARP Inhibitors-A Multicenter Italian Trial in Ovarian Cancer Observational Case-Control Study.
Turinetto M, Ricotti A, Marchetti C, Pisano C, Zamagni C, Cassani C, Malaguti P, Baldoni A, Scollo P, Scandurra G, Parisi A, Artioli G, Palaia I, Vertechy L, Bergamini A, Picardo E, Tuninetti V, Scotto G, Scambia G, Pignata S, Valabrega G. Turinetto M, et al. Among authors: valabrega g. Cancers (Basel). 2023 Dec 20;16(1):41. doi: 10.3390/cancers16010041. Cancers (Basel). 2023. PMID: 38201470 Free PMC article.
HER2-positive breast cancer cells resistant to trastuzumab and lapatinib lose reliance upon HER2 and are sensitive to the multitargeted kinase inhibitor sorafenib.
Valabrega G, Capellero S, Cavalloni G, Zaccarello G, Petrelli A, Migliardi G, Milani A, Peraldo-Neia C, Gammaitoni L, Sapino A, Pecchioni C, Moggio A, Giordano S, Aglietta M, Montemurro F. Valabrega G, et al. Breast Cancer Res Treat. 2011 Nov;130(1):29-40. doi: 10.1007/s10549-010-1281-5. Epub 2010 Dec 9. Breast Cancer Res Treat. 2011. PMID: 21153051
Modeling ErbB2-p130Cas interaction to design new potential anticancer agents.
Costamagna A, Rossi Sebastiano M, Natalini D, Simoni M, Valabrega G, Defilippi P, Visentin S, Ermondi G, Turco E, Caron G, Cabodi S. Costamagna A, et al. Among authors: valabrega g. Sci Rep. 2019 Feb 28;9(1):3089. doi: 10.1038/s41598-019-39510-w. Sci Rep. 2019. PMID: 30816273 Free PMC article.
Trastuzumab-related cardiotoxicity in the herceptin adjuvant trial.
Montemurro F, Redana S, Valabrega G, Martinello R, Aglietta M, Palmiero R. Montemurro F, et al. Among authors: valabrega g. J Clin Oncol. 2008 Apr 20;26(12):2052-3; author reply 2053-4. doi: 10.1200/JCO.2007.15.5044. J Clin Oncol. 2008. PMID: 18421060 No abstract available.
Secondary cytoreductive surgery, hyperthermic intraperitoneal intraoperative chemotherapy, and chemotherapy alone: a retrospective comparison of alternative approaches in relapsed platinum sensitive ovarian cancer.
Marocco F, Vaira M, Milani A, Genta S, Maggiorotto F, Magistris A, Cinquegrana A, Robella M, De Simone M, Aglietta M, Ponzone R, Valabrega G. Marocco F, et al. Among authors: valabrega g. Eur J Gynaecol Oncol. 2016;37(5):638-643. Eur J Gynaecol Oncol. 2016. PMID: 29787001
114 results